Kent, Stephen J.

What level of neutralising antibody protects from COVID-19?

Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 3,742

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 3,742

Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies

Lee, W. S., Wheatley, A. K., Kent, S. J., & DeKosky, B. J. (2020) · Nature Microbiology

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 676

Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19

Juno, J. A., Tan, H.-X., Lee, W. S., Reynaldi, A., Kelly, H. G., Wragg, K., Esterbauer, R., Kent, H. E., Batten, C. J., Mordant, F. L., et al. (2020) · Nature Medicine

SARS-CoV-2 and COVID-19 ResearchT-cell and B-cell Immunology

Cited by 437

Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19

Wheatley, A. K., Juno, J. A., Wang, J. J., Selva, K. J., Reynaldi, A., Tan, H.-X., Lee, W. S., Wragg, K. M., Kelly, H. G., Esterbauer, R., et al. (2021) · Nature Communications

SARS-CoV-2 and COVID-19 ResearchImmune responses and vaccinations

Cited by 351

Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection

Cromer, D., Juno, J. A., Khoury, D., Reynaldi, A., Wheatley, A. K., Kent, S. J., & Davenport, M. P. (2021) · Nature Reviews Immunology

SARS-CoV-2 and COVID-19 ResearchImmune responses and vaccinations

Cited by 265

Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines

Ju, Y., Carreño, J. M., Simon, V., Dawson, K., Krammer, F., & Kent, S. J. (2023) · Nature Reviews Immunology

SARS-CoV-2 and COVID-19 ResearchMonoclonal and Polyclonal Antibodies Research

Cited by 201

Cytotoxic CD4 T Cells—Friend or Foe during Viral Infection?

Juno, J. A., van Bockel, D., Kent, S. J., Kelleher, A. D., Zaunders, J. J., & Munier, C. M. L. (2017) · Frontiers in Immunology

T-cell and B-cell ImmunologyHIV Research and Treatment

Cited by 195

Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?

Kent, S. J., Khoury, D. S., Reynaldi, A., Juno, J. A., Wheatley, A. K., Stadler, E., John Wherry, E., Triccas, J., Sasson, S. C., Cromer, D., et al. (2022) · Nature Reviews Immunology

SARS-CoV-2 and COVID-19 ResearchImmune responses and vaccinations

Cited by 139

Neutralising antibodies predict protection from severe COVID-19

Cromer, D., Steain, M., Reynaldi, A., Schlub, T. E., Sasson, S. C., Kent, S. J., Khoury, D. S., & Davenport, M. P. (2022) · Nature Communications

SARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studies

Cited by 139

Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models

Khoury, D. S., Wheatley, A. K., Ramuta, M. D., Reynaldi, A., Cromer, D., Subbarao, K., O’Connor, D. H., Kent, S. J., & Davenport, M. P. (2020) · Nature Reviews Immunology

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 115

Decay of Fc-dependent antibody functions after mild to moderate COVID-19

Lee, W. S., Selva, K. J., Davis, S. K., Wines, B. D., Reynaldi, A., Esterbauer, R., Kelly, H. G., Haycroft, E. R., Tan, H.-X., Juno, J. A., et al. (2020) · Cell Reports Medicine

SARS-CoV-2 and COVID-19 ResearchMonoclonal and Polyclonal Antibodies Research

Cited by 80

Age-Associated Cross-reactive Antibody-Dependent Cellular Cytotoxicity Toward 2009 Pandemic Influenza A Virus Subtype H1N1

Jegaskanda, S., Laurie, K. L., Amarasena, T. H., Winnall, W. R., Kramski, M., De Rose, R., Barr, I. G., Brooks, A. G., Reading, P. C., & Kent, S. J. (2013) · The Journal of Infectious Diseases

Influenza Virus Research StudiesRespiratory viral infections research

Cited by 64

At Least Three Doses of Leading Vaccines Essential for Neutralisation of SARS-CoV-2 Omicron Variant

Singanallur, N. B., van Vuren, P. J., McAuley, A. J., Bruce, M. P., Kuiper, M. J., Gwini, S. M., Riddell, S., Goldie, S., Drew, T. W., Blasdell, K. R., et al. (2022) · Frontiers in Immunology

SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and Hesitancy

Cited by 15

At Least Three Doses of Leading Vaccines Essential for Neutralisation of SARS-CoV-2 Omicron Variant

Singanallur, N. B., van Vuren, P. J., McAuley, A. J., Bruce, M. P., Kuiper, M. J., Gwini, S. M., Riddell, S., Goldie, S., Drew, T. W., Blasdell, K. R., et al. (2022) · Frontiers in Immunology

SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and Hesitancy

Cited by 15